DETECTING NEONATAL SEPSIS USING MOLECULAR TECHNIQUES

使用分子技术检测新生儿败血症

• 批准号: 6521303
• 负责人: JEANNE ANN JORDAN
• 金额: $ 17.1万
• 依托单位: MAGEE-WOMEN'S RES INST AND FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-08-16 至 2004-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6521303
• 关键词: bacterial disease; clinical research; diagnosis design /evaluation; enzyme linked immunosorbent assay; human subject; newborn human (0-6 weeks); polymerase chain reaction

DESCRIPTION: (Adapted from the Investigator's Abstract): Approximately 150,000 to 500,000 infants greater than 34 weeks gestational age are admitted to NICUs annually who are at risk for systemic infection. These infants all receive systemic antibiotic therapy. However, the vast majority of these infants are not infected, but rather have symptoms that are secondary to other medical conditions. The current standard of care for evaluating neonatal sepsis is blood culturing, which lacks sensitivity and is not informative prior to at least 24 to 46 hours. As a result, there is prolonged use of antibiotic therapy in many newborns that could be shortened if a more rapid test to rule out sepsis was available. This application proposes to investigate two potential tests, a PCR-based amplification assay for detecting bacterial 16S ribosomal DNA and an ELISA-based assay for defensins, to determine their usefulness as early predictors of systemic neonatal infection.

描述：（改编自研究者摘要）：约 150,000 500,000 名胎龄大于 34 周的婴儿入住 NICU 有全身感染风险的人每年一次。这些婴儿都接受 全身抗生素治疗。然而，这些婴儿中的绝大多数 没有被感染，但有继发于其他医疗的症状 状况。目前评估新生儿败血症的护理标准是 血培养缺乏敏感性并且在之前没有提供信息 至少24至46小时。因此，长期使用抗生素治疗 在许多新生儿中，如果进行更快速的测试来排除可能会缩短 出现败血症。该应用程序建议研究两种潜在的 测试，一种基于 PCR 的扩增检测，用于检测细菌 16S 核糖体 DNA 和基于 ELISA 的防御素测定法，以确定其用途 新生儿全身感染的早期预测因子。